newsfilter
← Latest News
GlobeNewswire·

Galera Announces Presentation of Phase 3 ROMAN Long-term Follow-up Data at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting

Tumor outcomes and overall survival maintained in patients with HNC at one-year Cisplatin-related chronic kidney disease reduced by 50% in avasopasem patients compared to placebo at one-year Meta-analysis of ROMAN and